Effect of indole ethyl isothiocyanates on proliferation, apoptosis, and MAPK signaling in neuroblastoma cell lines

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 21, 2007, Pages 5846-5852

  Singh, Rakesh K ^a   Lange, Thilo S ^a,b   Kim, Kyukwang ^a   Zou, Yongping ^a   Lieb, Casey ^a   Sholler, Giselle L ^c   Brard, Laurent ^a  

^a Division of Gynecologic Oncology   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Cell signaling; Isothiocyanates; MAP kinases; Neuroblastoma; Structure activity relationship

Indexed keywords

7 METHYLINDOLE 3 ETHYL ISOTHIOCYANIC ACID; CAMPTOTHECIN; CASPASE 3; CASPASE 8; CASPASE 9; CISPLATIN; ETOPOSIDE; ISOTHIOCYANIC ACID DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; RAPAMYCIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; LUNG FIBROBLAST; NEUROBLASTOMA; NEUROBLASTOMA CELL; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; ISOTHIOCYANATES; MAP KINASE SIGNALING SYSTEM;

EID: 34748881392     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.08.032     Document Type: Article

References (46)

1. Brodeur G.M., Pizzo P.A., and Poplack D.G. Principles and Practice of Pediatric Oncology (Neuroblastoma). 4th ed. (2001), Lippencott-Raven, Philadelphia 895-937
2. Weinstein J.L., Katzenstein H.M., and Cohn S.L. Oncologist 8 (2003) 278
3. Matthay K.K., Perez C., Seeger R.C., Brodeur G.M., Shimada H., Atkinson J.B., Black C.T., Gerbing R., Haase G.M., Stram D.O., Swift P., and Lukens J.N. J. Clin. Oncol. 16 (1998) 1256
4. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., Swift P., Shimada H., Black C.T., Brodeur G.M., Gerbing R.B., and Reynolds C.P. N. Engl. J. Med. 341 (1999) 1165
5. Perez C.A., Matthay K.K., Atkinson J.B., Seeger R.C., Shimada H., Haase G.M., Stram D.O., Gerbing R.B., and Lukens J.N. J. Clin. Oncol. 18 (2000) 18
6. Maris J.M., and Matthay K.K. J. Clin. Oncol. 17 (1999) 2264
7. Goldsby R.E., and Matthay K.K. Paediatr. Drugs 6 (2004) 107
8. Matthay K.K., Atkinson J.B., Stram D.O., Selch M., Reynolds C.P., and Seeger R.C. J. Clin. Oncol. 11 (1993) 2226
9. Conaway C.C., Yang-ming Y., and Fung L.C. Curr. Drug. Metabol. 3 (2002) 233
10. Jackson S.J., Singletary K.W., and Venema R.C. Vascul. Pharmacol. 46 (2007) 77
11. Myzak M.C., Tong P., Dashwood W.M., Dashwood R.H., and Ho E. Exp. Biol. Med. 232 (2007) 27
12. Jakubikova J., Bao Y., and Sedlak J. Anticancer Res. 25 (2005) 3375
13. Johnson C.R., Chun J., Bittman R., and Jarvis W.D. J. Pharmacol. Exp. Ther. 309 (2004) 452
14. Wu X.J., and Hua X. Cancer Biol. Ther. 6 (2007) 5
15. Yuesheng Z., Tang L., and Gonzalez V. Mol. Canc. Therp. (2003) 1045
16. Heintz, A. P. M.; Odicino, F.; Maisonneuve, P.; Beller, U.; Benedet, J. L.; Creasman, W. T.; Nga, H. Y. S.; Pecorelli, S. FIGO Annual Report, 1996-1998.
17. Li Y., Wang Z., Kong D., Murthy S., Dou Q.P., Sheng S., Reddy G.P., and Sarkar F.H. J. Biol. Chem. 282 (2007) 21542
18. Kalkunte S., Swamy N., Dizon D.S., Granai C.O., and Brard L. J. Exp. Ther. Oncol. 5 (2006) 287
19. Satyan K.S., Swamy N., Dizon D.S., Singh R., Granai C.O., and Brard L. Gynecol. Oncol. 103 (2006) 261
20. Posner G.H., Cho C.G., Green J.V., Zhang Y., and Talalay P. J. Med. Chem. 37 (1994) 170
21. + [this compound has been previously reported; reference: Park, S.; Hayes, B. L.; Marankan, F.; Mulhearn, D. C.; Wanna, L.; Mesecar, A. D.; Santarsiero, B. D.; Johnson, M. E.; Venton, D. L. J. Med. Chem. 2003; 46, 936].
22. +.
23. +.
24. +.
25. +.
26. +.
27. +.
28. 5cells/T75 cell culture flask (Corning, New York, NY) and cultured to ∼80% confluency according to the suppliers recommendation.
29. Malich G., Markovic B., and Winder C. Toxicology 124 (1997) 179
30. 5 cells/dish), cultured to ∼80% confluency, and treated as indicated, rinsed in PBS, pH 7.4, scraped off, spun down in a microcentrifuge (10,000g, 5 min), and pellets resuspended in lysis buffer (1% NP-40, 20 mM Tris, pH 8.0, 137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM activated sodium orthovanadate, 10 μg/mL Aprotinin, 10 μg/mL Leupeptin, and Inhibitor Cocktail P-2714; Sigma-Aldrich, St. Louis, MO). Lysates were rocked at 4 °C for 5 min, sonicated (10 pulses 5 s), centrifuged at 140,000g for 10 min, and the protein concentration of the supernatant quantitated (BioRad protein estimation kit, Hercules, CA). The samples were boiled in the presence of 5× SDS-PAGE sample buffer and 50 μg total protein/lane was separated on 12% SDS-polyacrylamide gels and blotted onto PVDF membranes. The blots were blocked with 5% nonfat dried milk in PBST for 1 h at room temperature and incubated overnight at 4 °C with antibodies (purchased from Cell Signaling Technology, Beverly, MA) at a 1:1000 dilution in 5% BSA in PBST on a rotating platform. After washing in PBST the blots were incubated with secondary antibody (peroxidase-conjugated antibodies; Amersham Pharmacia Biotech, Piscataway, NJ). The bands were visualized by enhanced chemiluminescence and autoradiography (F-Bx810 Film, Pheonix, Hayward, CA).
31. Kim D., Cheng G.Z., Lindsley C.W., Yang H., and Cheng J.Q. Curr. Opin. Investig. Drugs 6 (2005) 1250
32. Mansouri A., Ridgway L.D., Korapati A.L., Zhang Q., Tian L., Wang Y., Siddik Z.H., Mills G.B., and Claret F.X. J. Biol. Chem. 278 (2003) 19245
33. Cuadrado A., Garci{dotless}a-Fernandez L.F., Gonzalez L., Suarez Y., Losada A., Alcaide V., Martinez T., Fernandez-Sousa J.M., Sanchez-Puelles J.M., and Munoz A. J. Biol. Chem. 278 (2003) 241
34. Brozovic A., and Osmak M. Cancer Lett. 251 (2007) 1
35. Brozovic A., Fritz G., Christmann M., Zisowsky J., Jaehde U., Osmak M., and Kaina B. Int. J. Cancer 112 (2004) 974
36. Zanke B.W., Boudreau K., Rubie E., Winnett E., Tibbles L.A., Zon L., Kyriakis J., Liu F.-F., and Woodgett J.R. Curr. Biol. 6 (1996) 606
37. Chen Y.-R., Wang X., Templeton D., Davis R.J., and Tan T.-H. J. Biol. Chem. 271 (1996) 31929
38. Salvesen G.S., and Abrams J.M. Oncogene 23 (2004) 2774
39. Thornberry N.A., and Lazebnik Y. Science 281 (1998) 1312
40. Stupack D.G., Teitz T., Potter M.D., Mikolon D., Houghton P.J., Vincent J.K., Lahti J.M., and Cheresh D.A. Nature 439 (2006) 95
41. 3/well) were plated into 96-well flat-bottomed plates (Corning, Inc., Corning, NY) and allowed to attach overnight before treatment as indicated in fresh complete medium. BrdU (10 μM final concentration) was added and the cells grown for additional 6 h. After various wash steps the cells were fixed and incubated for 2 h at 37 °C with an anti-BrdU antibody-peroxidase conjugate and immune complexes were detected by addition of a tetramethyl-benzidine substrate solution according to the manufacturer's recommendation. The reaction was stopped by adding 50 μL of 1 M sulfuric acid, and the absorbance was measured with an ELISA plate reader (Thermo Labsystems, Waltham, MA) at 450 nm. Blank wells were incubated with the anti-BrdU antibody and the background absorbance was subtracted from all other values. In this assay, the color intensity correlates directly to the amount of BrdU incorporated into the DNA, which in turn represents proliferation. Experiments were performed in triplicate; data are expressed as means of the triplicate determinations (X ± SD) of a representative experiment in % of absorbance of untreated cells [100%]; Ref:. Gratzner H.G. Science 218 (1982) 474
42. 5 cells/dish), allowed to attach overnight, and treated for 48 h as indicated. At the end of the incubation period detached cells were collected in 15 mL polypropylene centrifuge tubes along with the medium; culture dishes were washed once with PBS, adherent cells scraped off and combined in the same tube. After centrifugation (250g, 5 min) cells were fixed (ice-cold 70% ethanol for 30 min) followed by incubation with 50 μg/mL of propidium iodide and 100 μg/mL of RNase for 30 min at 37 °C in the dark. Data were acquired on a BD FACSort flow cytometer using CellQuest software (BD Immunocytometry Systems, San Jose, CA) and analyzed using ModFit LT software (Verity Software House, Inc., Topsham, ME). Ten thousand events were analyzed for each sample. Appropriate gating was used to select the single cell population NB cells. The same gate was used on all samples, ensuring that the measurements were made on a standardized cell population.
43. Mazumder S., DuPree E.L., and Almasan A. Curr. Cancer Drug Targets 4 (2004) 65
44. Gladden A.B., and Diehl J.A. Cancer Cell 4 (2003) 160
45. Pines J. Nature Cell. Biol. 1 (1999) 73
46. Stillman B. Science 274 (1996) 1659